RALEIGH, N.C. & WASHINGTON--(BUSINESS WIRE)--BioPontis Alliance, LLC, announced today at the 2011 BIO International Convention in Washington DC that it has entered into a Translational Technology Development agreement with Pfizer Inc. The agreement is an element of BioPontis Alliance’s unique business model which combines translational drug research with its own asset based investment fund. Pfizer is the second leading pharmaceutical company to join the alliance structure at BioPontis Alliance, which is a first-in-kind vehicle for capturing innovative science from academia and doing the necessary work to potentially translate discoveries into drug candidates for further development by pharmaceutical companies like Pfizer.
